Replimune Raises $30 Million in Series A Funding for Cancer Immunotherapy

Replimune, a UK-based developer of oncolytic immunotherapies for cancer treatment, has secured $30 million in Series A funding led by Atlas Venture with participation from existing investors Forbion Capital Partners and Omega Funds

Replimune is developing proprietary oncolytic immunotherapies to improve both direct anti-tumor effects and the potency of the immune response

The company intends to advance these therapies through clinical trials and combine them with checkpoint blockade

Replimune also plans to collaborate with companies developing checkpoint blockade or other complementary immuno-oncology drugs.